# Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

> **NCT04990479** · PHASE1 · TERMINATED · sponsor: **Nouscom SRL** · enrollment: 7 (actual)

## Conditions studied

- Melanoma (Skin)
- Non-Small-Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** GAd-PEV
- **BIOLOGICAL:** MVA-PEV

## Key facts

- **NCT ID:** NCT04990479
- **Lead sponsor:** Nouscom SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-11
- **Primary completion:** 2024-03-05
- **Final completion:** 2024-03-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Terminated by Sponsor
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04990479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04990479, "Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04990479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*